Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study

Authors:

Abstract
No abstract available
Funding Information
  • Memorial Sloan Kettering Cancer Center (P30 CA008748)
  • Genentech Foundation

This publication has 21 references indexed in Scilit: